This new article publication from Acta Pharmaceutica Sinica B , discusses a bispecific killer engager for targeted depletion of PD-1 positive lymphocytes. Bispecific killer cell engagers (BiKEs) are a ...

Pfizer’s sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer ...

Neoadjuvant PD-1 blockade in dMMR tumors "could potentially eradicate the need for chemotherapy, radiation, and surgery in ...

The FDA has approved Akeso’s penpulimab-kcqx, a PD-1 monoclonal antibody, for two indications treating nasopharyngeal carcinoma (NPC). The drug is now indicated in combination with chemotherapy as a ...

Title: Targeting PD-1 with self-delivering RNAi ... a key regulator of gene expression. PH-894 enhances NK cell activation and proliferation without off-target effects, presenting a promising ...